Objectives: The objective of this study was to evaluate the proficiency of Spanish laboratories with respect to accurate susceptibility testing and the detection and interpretation of quinolone resistance phenotypes in Enterobacteriaceae.
Introduction
Over the past three decades, quinolone resistance has increased in Enterobacteriaceae among human and veterinary isolates. Fluoroquinolone resistance mainly occurs as a result of mutations in chromosomal genes encoding the quinolone targets DNA gyrase and topoisomerase IV. 1 Mutation-driven mechanisms also include loss of porins and overexpression of one or more of several efflux pumps (such as AcrAB-TolC), which can lead to resistance or decreased susceptibility to b-lactams and fluoroquinolones. 2 Three plasmid-mediated quinolone resistance (PMQR) mechanisms have also been described: (i) Qnr proteins (members of the pentapeptide repeat protein family, which bind to DNA gyrase and topoisomerase IV and protect the quinolone targets); (ii) the Aac(6 ′ )-Ib-cr enzyme (which acetylates not only aminoglycosides but also ciprofloxacin and norfloxacin); and (iii) QepA and OqxAB plasmid-mediated efflux pumps. 3 Five types of qnr determinants encoded by the qnrA, qnrB, qnrS, qnrC and qnrD genes have been described in Enterobacteriaceae. 3, 4 Several of these mechanisms must be combined to achieve a clinical level of resistance.
Enterobacteriaceae, particularly Escherichia coli, Klebsiella spp. and Enterobacter spp., are among the most common organisms causing community, nosocomial and opportunistic infections. The emergence of a very close association between quinolone resistance and resistance to other antimicrobial agents, particularly b-lactams and aminoglycosides, is a critical problem when managing such infections. One of the most striking features of these species is their remarkable capacity for developing antibiotic resistance. The prevalence of infections caused by MDR Enterobacteriaceae strains is increasing globally (with resistance rates at around 30%; http://www.eurosurveillance.org/), 5 often rendering antibiotic treatments useless and causing a significant rise in the morbidity and mortality of affected patients.
The task of clinical microbiologists to properly perform antimicrobial susceptibility testing and interpretation and carry out complementary phenotypic/genotypic tests proficient in detecting the resistance mechanisms involved is the necessary first step for implementing appropriate treatments and antibiotic use policies. 6 In this regard, there are no reliable phenotypic tests available for detecting PMQR mechanisms, either for strains with borderline susceptibility to these determinants alone or for resistant strains harbouring additional chromosomal mutations. 4, 7 One disturbing consequence of this situation is the underestimation of the prevalence of acquired and/or mutational resistance mechanisms, which often leads to the application of erroneous antibiotic treatments and subsequent clinical failure. There is limited information about the proficiency of clinical microbiology laboratories in overcoming this challenge. Some previous studies have shown the importance of correctly evaluating resistance to other antimicrobial agents, such as b-lactams, in wellcharacterized strains of Enterobacteriaceae or Pseudomonas aeruginosa.
8, 9 The objective of this study was to assess the ability of Spanish clinical microbiology laboratories to properly carry out susceptibility testing and to infer underlying resistance mechanisms in a collection of well-characterized Enterobacteriaceae strains, including those with complex combinations of mutational and transferable quinolone resistance mechanisms causing lowlevel quinolone resistance (LLQR) phenotypes.
Methods
Bacterial strains, characterization of resistance mechanisms and susceptibility testing Thirteen Enterobacteriaceae strains, coded CC-00 to CC-12, were selected for this study (Table 1) . They included 12 clinical isolates or laboratory strains (CC-01 to CC-12) with different chromosomal and/or horizontally acquired resistance mechanisms and one reference strain: E. coli ATCC 25922 (CC-00). Identification of the strains, antimicrobial susceptibility testing and confirmation of the quinolone resistance mechanisms were verified independently at the two reference laboratories used for this study: the Department of Microbiology, School of Medicine, University of Seville, Seville, Spain, and the Service of Microbiology, University Hospital Marqués de Valdecilla, Santander, Spain. API 20-E (bioMérieux, Marcy-l'Étoile, France) was used for species identification. Testing for susceptibility to ciprofloxacin, levofloxacin, moxifloxacin, ofloxacin, norfloxacin and nalidixic acid was performed in duplicate at both the reference centres by disc diffusion, CLSI broth microdilution and Etest (bioMérieux, Madrid, Spain). The 2013 CLSI and EUCAST (http://www.eucast.org/clinical_breakpoints/) breakpoints were used to interpret clinical categories. 
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Data analysis
Analysis of results focused on three aspects: (i) a descriptive analysis of susceptibility testing methods, breakpoints applied, clinical categories (CCs) assigned and discrepancies between centres deriving from these;
(ii) an analysis of errors detected in susceptibility testing results [minor errors (mEs), major errors (MEs) and very major (VMEs), defined according to standard criteria] compared with reference values; 12 and (iii) an analysis of the ability of participating laboratories to accurately infer the underlying resistance mechanisms.
Results
Descriptive analysis of susceptibility testing methods, breakpoints applied, CCs assigned and derived discrepancies Ninety percent of participating laboratories used automatic or semi-automatic devices for routine susceptibility testing. These included the MicroScan WalkAway (Dade MicroScan Inc., West Sacramento, CA, USA; n ¼ 30, 48%), Vitek 2 (bioMé rieux; n ¼ 19, 30%), the Wider (Francisco Soria Melguizo, Madrid, Spain; n ¼ 5, 8%) and Phoenix (BD Biosciences, Sparks, MD, USA; n ¼2, 3%) systems. The remaining 10% used manual methods. Nevertheless, several automatic system users also performed complementary manual tests (up to 15%) to check certain borderline susceptibility values (mainly for CC-03, CC-07 and CC-09 strains). CLSI breakpoints were applied for 71% of determinations and EUCAST breakpoints for the remaining 29%.
The overall (all antibiotics/strain combinations) raw discrepancy rate due exclusively to the differential use of breakpoints was 21.8% (Table 2 ). Ofloxacin and norfloxacin were often involved in this kind of discrepancy, with particularly high percentages (38.4% -46.1%); CC-03 and CC-10 strains [qnrS2+aac(6 ′ )-Ib-cr and GyrA Ser83Leu + GyrA Asp87Asn + ParC Ser80Arg +DmarR, respectively] showed the highest discrepancy rates (50%). High breakpoint-related discrepancies were also found for CC-07, CC-08, CC-09 and CC-11 (33.3%), all of which had chromosomally mediated mechanisms. On the other hand, CC-00, CC-04, CC-05 and CC-06 showed no breakpoint-related discrepancies (Table 2) . When the RCC was modified to ICC, the discrepancy rate due exclusively to the differential use of breakpoints decreased considerably when some in the susceptible category were re-coded as I(r) (interpreted as intermediate susceptibility due to a less susceptible phenotype, e.g. with MICs ≥0.125 mg/L for ciprofloxacin; Table 2 ).
ICCs provided by participating centres and the discrepancies between them are shown in Figure 1 . There was a high degree of consensus among centres for WT strains (CC-00) and for strains with high-level resistance patterns, such as CC-05, CC-06 and CC-11 [harbouring triple quinolone resistance-determining region (QRDR) modification + aac(6 ′ )-Ib-cr+oqxAB, triple QRDR modification + qepA1 and triple QRDR modification +DmarR, respectively]. On the other hand, there was less consensus about some antimicrobial/strain combinations, such as ciprofloxacin and CC-03, CC-07 and CC-09 strains [harbouring qnrS2+aac(6 ′ )-Ib-cr, GyrA Ser83Leu+ OmpK35 2 + efflux and double QRDR modification + DmarR, respectively, with MICs in the range of 0.5 -2 mg/L], and levofloxacin and CC-01, CC-03, CC-07, CC-09 and CC-10 strains (MICs in the range of 0.5-2 mg/L).
Analysis of errors (mEs, MEs and VMEs) in susceptibility testing results
Quinolone MICs, RCCs obtained after applying CLSI and EUCAST criteria and consensus ICCs obtained at the two reference centres are shown in Table 2 . The distributions of discrepancies and categorical error rates by antibiotic and strain are shown in Tables 3 and 4 , respectively. The percentage of VMEs (false susceptibility) for all quinolones was well below 2%, and only ofloxacin and moxifloxacin showed higher rates for raw VMEs (6.6%), which reduced to 0% and 2.9%, respectively, in the interpreted VMEs (Table 3 ) (these VMEs were associated with manual methods: disc diffusion for ofloxacin and agar dilution for moxifloxacin; data not shown). These errors were particularly associated with the CC-03 [qnrS2 +aac(6 ′ )-Ib-cr] strain and were almost exclusively observed among MicroScan WalkAway automated systems users (50% of total raw VMEs with respect to this strain) ( Table 4 ). The percentages of MEs (false resistance) were always ,10%, except for the raw MEs for ofloxacin and nalidixic acid (22.2% and 19.1%, respectively) and the interpreted MEs for nalidixic acid (27.1%). Eighty-five percent of raw MEs for ofloxacin occurred in the CC-01 and CC-02 strains. The high percentage of mEs observed was not surprising, given the MIC values exhibited by several strains in this collection, which, in many cases, were on the borderline between two CCs (Tables 2 and 3 ).
The analysis of categorical errors according to strain (Table 4 ) revealed that those with the highest rates of raw VMEs were CC-03 [harbouring qnrS2 and aac(6 ′ )-Ib-cr, 5.8%] and CC-08 (single GyrA and ParC mutation, 3.3%). These percentages dropped to 0% when interpreted categories were applied. VMEs in the CC-03 strain were linked to ciprofloxacin and moxifloxacin and those in CC-08 to norfloxacin. CC-03 was also a strain that gave a high rate of raw MEs (13.8%) linked with nalidixic acid (73% of these). Highest rates of raw MEs were observed for CC-02 strains (qnrA1) (21.9%) in association with nalidixic acid; CC-07 (single GyrA mutation with loss of porins and efflux) (22.6%) linked to norfloxacin; and CC-10 (double GyrA and single ParC mutation) (20.4%), linked to ciprofloxacin (71% of these) and levofloxacin (18%). A significant increase in interpreted ME values was observed for CC-02 and CC-03 strains (57.6% and 42.6%, respectively), due to the fact that some raw susceptible strains were modified to the intermediate category using ICC criteria, which obviously reduced the number of strains finally defined as Rodriguez-Martinez et al. Table 1 ). a Determined in duplicate by the two reference centres using the CLSI broth microdilution method. susceptible. Additionally, interpretation of these results should take into account the fact that some of the quinolones (e.g. ciprofloxacin and nalidixic acid) were tested by most of the centres while others (e.g. moxifloxacin and norfloxacin) were tested only by a lower number of centres. VMEs were not found for the Vitek 2 and Wider systems compared with the MicroScan WalkAway (0.4% and 1% for raw and interpreted data, respectively). Among all determinations performed using the MicroScan WalkAway, two raw VMEs and four interpreted VMEs were found (affecting ciprofloxacin and norfloxacin in the CC-03, CC-07 and CC-08 strains). The Wider system accounted for the lowest percentage of raw MEs overall, followed by the MicroScan WalkAway and Vitek 2 systems; after interpretation, the percentage of MEs was still in the same order. The fluoroquinolone giving the highest percentage of raw MEs was norfloxacin among Wider users, levofloxacin among Vitek 2 users and ciprofloxacin among MicroScan WalkAway users. The Wider system showed the lowest rate of raw mEs, followed by the MicroScan WalkAway and the Vitek 2.
Ability of centres to detect acquired PMQRs and to infer resistance mechanisms
An analysis of errors of inference is shown in Table 5 , in which strains CC-01, CC-02, CC-03 and CC-04 (all with LLQR and harbouring PMQR mechanisms) are highlighted as those giving the highest percentage of errors, documented in 11.3% -54.8% of centres. One of the most important aspects was that acquired PMQR genes were not detected in certain strains. In such cases, laboratories attributed resistance exclusively to mutational mechanisms, with percentages of .40% in the strains specified. By contrast, PMQR genes were inferred in strains harbouring only chromosomal mechanisms (CC-07, CC-08, CC-09, CC-10, CC-11 and CC-12).
Discussion
The growing prevalence of quinolone resistance in Enterobacteriaceae severely compromises the therapeutic arsenal available. 1, 13, 14 The complexity of the mechanisms involved also affects the ability of the clinical microbiology laboratory to perform proper standardized antimicrobial susceptibility tests. This situation may cause greater concern with borderline resistance phenotypes. The detection of specific resistance mechanisms is particularly important for guiding therapy and infection control strategies. 8, 9 It was this clinical challenge that motivated this large multicentre study, in which we evaluated the proficiency of 62 Spanish laboratories with respect to accurate susceptibility testing and detection of quinolone resistance phenotypes in a collection of well-characterized Enterobacteriaceae strains showing different combinations of mutational and transferable quinolone resistance mechanisms.
Of the various aspects that had a significant impact on discrepancies in the susceptibility testing results provided by participating centres, the differential application of the currently nonharmonized CLSI or EUCAST breakpoints should be mentioned. EUCAST breakpoints were used in only 29% of the participating centres, although this represents a significant increase when compared with similar Spanish studies performed in 2001 and Table 3 . a RCC and ICC results from participating laboratories were compared with reference centre values and discrepancies were classified as mE, ME and VME, following standard criteria.
b
The most favourable CC for the evaluated centre was chosen when the MIC value (obtained by the reference centres) gave rise to two different CCs according to EUCAST/CLSI breakpoints.
In this case, the breakpoints chosen were those most in concordance with the CC issued by the evaluated centre.
c
The denominator is the number of susceptibility-testing determinations per antibiotic.
d
The denominator is the number of susceptible strains per antibiotic.
e
The denominator is the number of resistant strains per antibiotic.
f
The denominator is the total number of susceptibility determinations.
Challenges to accurate susceptibility testing and interpretation of quinolone resistance 2043 JAC Table 4 . Distribution of categorical error rates by tested strain Table 1 ). a RCC and ICC results from participating laboratories were compared with reference centre values and discrepancies were classified as mE, ME and VME, following standard criteria.
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b The most favourable CC of the evaluating centre was chosen when an MIC value (obtained by reference centres) gave rise to two different CCs according to EUCAST/CLSI breakpoints. In this case, the breakpoints chosen were those showing most concordance with the CC issued by the evaluating centre. c The denominator is the number of susceptibility-testing determinations for each strain. d The denominator is the number of susceptibility-testing determinations for susceptible strains. e The denominator is the number of susceptibility-testing determinations for resistant strains.
2011, in which 100% and 86% of the centres, respectively, applied CLSI breakpoints. 8, 9 Furthermore, this value is expected to increase significantly in the near future once the current institutional recommendations in Europe are followed. The application of European breakpoints has increased significantly in Spain, due particularly to the 2012 constitution of the Spanish Antibiogram Committee (Coesant), whose main commitment is to endorse EUCAST breakpoints. 15 Regarding the discrepancies that derived from breakpoints, ofloxacin and norfloxacin were the antibiotics most affected. These discrepancies may be particularly important in PMQRproducing strains (such as CC-03) or those with combinations of two or three mutational modifications (such as CC-07, CC-08, CC-09 and CC-10), since several strains that showed mutational resistance mechanisms or relevant acquired PMQR genes, such as qnrS2 and aac(6 ′ )-Ib-cr, were reported as susceptible according to CLSI breakpoints but resistant according to EUCAST. Less relevant are discrepancies deriving from different ciprofloxacin or levofloxacin breakpoints, where discrepancies were mostly reported as intermediate according to CLSI breakpoints and resistant according to EUCAST breakpoints. 10, 11 The method used to carry out susceptibility testing was another source of discrepancy in the results between centres. Most centres (90%) used semi-automatic or automatic devices, mainly the MicroScan WalkAway, Vitek 2 and Wider systems. Vitek 2 and Wider devices did not show VMEs, although they were used considerably less than the MicroScan WalkAway. Regarding MEs, both raw and after interpretation, the lowest percentage overall corresponded to the Wider, followed by the MicroScan WalkAway and then the Vitek 2 systems. Among the antibiotics tested, moxifloxacin and ofloxacin had the highest recorded VME rates. Among the studied strains, CC-03 [a combination of qnrS2 plus aac(6 ′ )-Ib-cr] and CC-08 (single mutation in GyrA and ParC) were those associated with a higher rate of VMEs overall. These data indicate that borderline phenotypes may imply a source of discrepancy for susceptibility testing in clinical microbiology and to have consequences for treatment outcome. 16, 17 A further source of divergent results concerns the interpretive reading of susceptibility testing data, and hence the reporting of ICCs. This ICC parameter is important because the in vivo activity of quinolones in the clinical setting is related to MIC values and AUC/MIC or C max /MIC, which are good indicators of a favourable outcome for quinolone treatment. 18 Consequently, it may be assumed from these indicators that an increase in the MIC of a quinolone (of even just a few dilution steps) will have a negative impact on its therapeutic efficacy. In our study, 15% of all susceptibility determinations involved a change in the final CC, with percentages of .40% for some antibiotic and strain combinations. A high percentage of discrepancies in ICCs involved a change to intermediate susceptibility [I(r)] when interpreted at the reference centres; e.g. an MIC of ≥0.125 mg/L for ciprofloxacin was modified to intermediate susceptibility, depending on the associated resistant molecular mechanism (although it should be noted that PMQR mechanisms could be present in isolates with lower MICs values, as reported). 19 We suggest that the current breakpoints defined by EUCAST/CLSI be re-evaluated, and that the already agreed general principles for the clinical categorization of antibiogram results for Salmonella could also be applied to other enterobacteria when considering severe infections. 10, 11 Various well-known factors that limit the efficiency of interpretive readings include a lack of knowledge about the basis of resistance in a significant proportion of medical microbiologists; unknown factors affecting resistance in clinical strains; low-level resistance mechanisms; and certain mechanisms that may be camouflaged as a result of the complex interplay of intrinsic and acquired resistance mechanisms. For example, it is not possible to infer PMQR mechanisms directly when they are associated with QRDR modifications that confer a high level of nalidixic acid resistance; meanwhile the PMQR phenotype is generally characterized by reduced susceptibility to fluoroquinolones, with susceptibility to nalidixic acid in the absence of QRDR modifications. 20 -22 The implementation of expert Challenges to accurate susceptibility testing and interpretation of quinolone resistance 2045 JAC systems in most automatic/semi-automatic systems may help in this task. 23, 24 Recommendations for interpretive reading, inferring and detecting resistance mechanisms have never been issued by CLSI or EUCAST, despite the fact that the breakpoints are certainly not adapted to overcoming PMQR mechanisms. As observed in our study, a combination of one to three relevant mechanisms of mutational resistance or PMQR determinants frequently yields a borderline MIC. This, therefore, is a major source of conflicting results in the absence of an interpretive reading of the antibiogram. The pharmacokinetic parameter for the clinical efficacy of quinolones is the AUC/MIC. Small variations in MIC values may decrease this parameter and affect the treatment outcome. In this way, these low-level resistant phenotypes (breakpoint borderlines) could have clinical relevance leading to in vivo resistance. In particular, it has been reported that PMQR mechanisms can reduce fluoroquinolone activity in vivo. 25, 26 In this sense, the epidemiological cut-off for ciprofloxacin in E. coli, established as 0.032 mg/L according to EUCAST (www.eucast.org), seems to be useful for LLQR detection.
Taken together, the data obtained in this work clearly suggest that the use of different breakpoints and systems, as well as the complexity of the mechanisms that lead to reduced susceptibility and produce borderline phenotypes, may have important consequences for the treatment and control of infections caused by these microorganisms.
